Table 2 Predictors of cure

Gender

 Female

 Male

73 (43.5)

73 (39)

Referent

0.833 (0.546–1.273)

0.399

Age (years)

 ≤ 40

 > 40

112 (43.6)

34 (34.7)

Referent

0.688 (0.424–1.115)

0.129

Referent

0.990 (0.488–2.009)

0.979

Baseline body weight (kg)

 < 40

 ≥ 40

42 (33.9)

104 (45)

Referent

1.599 (1.016–2.516)

0.042

Referent

1.661 (0.922–2.994)

0.091

Marital status

 Single

 Married

 Widow

54 (47.4)

90 (38.6)

2 (25)

Referent

0.699 (0.445–1.099)

0.370 (0.072–1.913)

0.121

0.236

Referent

0.737 (0.394–1.378)

0.396 (0.045–3.484)

0.339

0.404

History of TB treatment

 No

 Yes

14 (58.3)

132 (39.9)

Referent

0.474 (0.204–1.098)

0.082

Referent

0.527 (0.186–1.492)

0.228

History of MDR-TB treatment

 No

 Yes

97 (42.2)

49 (39.2)

Referent

0.884 (0.567–1.379)

0.587

Baseline sputum smear grading

 Negative

 Scanty* + 1†

 + 2‡ + 3§

 Not available

27 (48.2)

51 (46.4)

67 (75.7)

1 (20)

Referent

0.928 (0.487–1.768)

0.615 (0.336–1.125)

0.269 (0.028–2.558)

0.821

0.115

0.253

Referent

1.144 (0.491–2.665)

0.603 (0.276–1.318)

0.709 (0.061–8.238)

0.756

0.205

0.783

Co-morbidity

 No

 Yes

120 (40.1)

26 (46.4)

Referent

1.293 (0.728–2.295)

0.380

Number of resistant drugs

 4–6

 7–8

 > 8

46 (46)

54 (32.5)

46 (51.7)

Referent

0.566 (0.340–0.943)

1.256 (0.709–2.226)

0.029

0.435

Referent

0.523 (0.257–1.066)

1.010 (0.365–2.791)

0.075

0.985

Resistance to all five FLD

 No

 Yes

79 (37.3)

67 (46.9)

Referent

1.484 (0.965–2.283)

0.072

Referent

1.798 (0.760–2.674)

0.058

Resistance to ethambutol

 No

 Yes

39 (42.4)

107 (40.7)

Referent

0.932 (0.576–1.508)

0.775

Resistance to pyrazinamide

 No

 Yes

43 (41)

103 (41.2)

Referent

1.010 (0.536–1.606)

0.965

Resistance to streptomycin

 No

 Yes

53 (37.9)

93 (43.3)

Referent

1.251 (0.810–1.934)

0.313

Resistance to ethionamide

 No

 Yes

127 (41)

19 (42.2)

Referent

1.053 (0.559–1.984)

0.873

Resistance to SLIs

 No

 Yes

85 (43.4)

61 (38.4)

Referent

0.813 (0.531–1.245)

0.341

Use of moxifloxacin

 No

 Yes

46 (39.0)

100 (42.2)

Referent

1.142 (0.728–1.793)

0.563

Use of para-amino salicylic acid

 No

 Yes

11(27.5)

135 (42.9)

Referent

1.977 (0.954–4.099)

0.067

Referent

1.539 (0.620–3.823)

0.330

Use of clarithromycin

 No

 Yes

64 (43.8)

82 (39.2)

Referent

0.827 (0.539–1.270)

0.386

Use of co-amoxiclav

 No

 Yes

47 (39.5)

99 (41.9)

Referent

1.107 (0.706–1.735)

0.657

Use of bedaquiline

 No

 Yes

135 (41.9)

11 (33.3)

Referent

0.693 (0.325–1.476)

0.342

Use of clofazimine

 No

 Yes

71 (43.3)

75 (39.3)

Referent

0.847 (0.554–1.294)

0.442

Use of linezolid

 No

 Yes

43 (45.7)

103 (42.2)

Referent

1.155 (0.730–1.827)

0.538

Use of amikacin

 No

 Yes

117 (41.2)

29 (40.8)

Referent

0.986 (0.581–1.673)

0.957

Use of capreomycin

 No

 Yes

38 ( 40.4)

108 (41.4)

Referent

1.040 (0.644–1.681)

0.872

Use of high dose isoniazid

 No

 Yes

138 (43.1)

8 (22.9)

Referent

0.391 (0.172–0.887)

0.025

Referent

0.433 (0.57–1.195)

0.106

Use of ethambutol

 No

 Yes

118 (40.7)

28 (43.1)

Referent

1.103 (0.640–1.900)

0.724

SCC at month 2

 No

 Yes

85 (32.9)

61 (62.9)

Referent

3.449 (2.119–5.612)

 < 0.001

Referent

0.658 (0.310–1.394)

0.274

SCC at month 4

 No

 Yes

44 (22)

102 (65.8)

Referent

6.823 (4.259–10.931)

 < 0.001

Referent

1.037 (0.388–2.773)

0.942

SCC at month 6

 No

 Yes

21 (12.7)

125 (66.1)

Referent

12.770 (7.348–21.923)

 < 0.001

Referent

15.603 (6.168–39.467)

 < 0.001